1. Update on the Management of Atopic Dermatitis

2. Background

3. Burden of AD: Severe Disease

4. Burden of AD: Severe Disease

5. Impact of AD on Quality of Life in Children

6. AD Is Associated With Depression and Suicidal Ideation

7. Comorbidity

8. Psychiatric Comorbidity Associated With AD

9. The Psychiatric March of AD

10. Skin Inflammation Directly Affects Central Nervous System Functioning: A Chronic Feedback Loop

11. UK Treatment Guidelines: Children With AD

12. EU Treatment Guidelines: Children With AD

13. Limitations of Conventional Treatment: AEs With Topical Therapies

14. Limitations of Conventional Treatment: AEs With Systemic Therapies

15. Unmet Need for Systemic Therapy for Children With AD

16. Emerging Therapies

17. Cytokines Trigger Pro-Allergic Inflammation

18. Acute and Chronic Phases of AD

19. New Therapeutic Targets for AD

20. Milestones in the Treatment of AD

21. Efficacy of Dupilumab in Patients With Moderate to Severe AD

22. Safety Profile of Dupilumab

23. Targeting PDE4 With Crisaborole

24. Efficacy of Crisaborole in Children and Adults With Mild to Moderate AD

25. Safety Profile of Crisaborole

26. JAK Mediates Signal Transduction Induced by Key Cytokines in AD Pathogenesis

27. Randomized Phase 2 Trial of Topical Tofacitinib (JAK1, JAK3 Inhibitor) in Patients With Mild to Moderate AD: Efficacy

28. Randomized Phase 2 Trial of Topical Tofacitinib (JAK1, JAK3 Inhibitor) in Patients With Mild to Moderate AD: Safety

29. Targeting IL-13

30. Targeting IL-31

31. Targeting IL-17C: Phase 1 Trial of MOR106

32. Targeting IL-22: Randomized Phase 2 Trial of Fezakinumab in Moderate to Severe AD

33. Targeting TSLP: Randomized Phase 2 Trial of Tezepelumab in Moderate to Severe AD

34. Concluding Remarks

35. Abbreviations

36. Abbreviations (cont)